EVALUATION OF THE EFFICACY AND SAFETY OF DOMESTIC GONADOTROPIN RELEASING HORMONE ANALOGUE IN THE TREATMENT OF GIRLS WITH IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: HUANG, Juyi (Cathay Medical Care Corporate Sijhih Cathay General Hospital, New Taipei City, China Taiwan)
- Co-author(s): Ju-yi Huang
Leuprorelin is subcutaneously administered once every 4 weeks for the suppression of gonadotropic activation and delaying epiphyseal closure in children.
We retrospectively reviewed the hospital medical records with ICD-9:2591 from Aug 2007 to Dec 2014. All subjects were treated with Leuprorelin at least 1 year. After a year of GnRH agonist.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.